Regeneron VGFTe-OD-1411 PANORAMA
Posted by: Georgia Retina in
Research Title: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Sponsor: Regeneron Pharmaceuticals Principal Investigator: Michael Jacobson, M.D. Description: The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to…
Read More
RIDE FVF4168g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RIDE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More RISE FVF4170g
Posted by: Georgia Retina in
Research Title: A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus (RISE) Sponsor: Genentech Principal Investigator: Michael Jacobson, M.D. Description: This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection in patients with CSME-CI secondary to diabetes mellitus (Type…
Read More Roche BP29647 AVENUE
Posted by: Georgia Retina in
Research Title: A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RG7716 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Sponsor: Hoffmanm-La Roche Principal Investigator: Jay Stallman, M.D., F.A.C.S. Description: This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy…
Read More KalVista KVD011-201
Posted by: Georgia Retina in
Research Title: A randomized sham-controlled double-masked Phase 2a study of the efficacy, safety and tolerability of the intravitreal plasma kallikrein inhibitor, KVD001, in subjects with center-involving diabetic macular edema (ciDME) who have had prior anti-vascular endothelial growth factor (VEGF) treatment. Sponsor: KalVista Pharmaceticals, Ltd. Principal Investigator: Robert Stoltz, M.D., Ph.D Description: The purpose of this study is to evaluate…
Read More AART C-02-60
Posted by: Georgia Retina in
Research Title: Anecortave Acetate Risk-Reduction Trial (AART) Sponsor: Allergan Principal Investigator: Atul Sharma, M.D. Description: A 48-month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months. Start Date: March 2006 Recruitment: Completed Project Personnel: Leslie Marcus, CCRC Location(s): Riverdale; 155 Medical Way, Suite E, Riverdale, GA 30274
Read More Allergan 1771-201-008 MAPLE
Posted by: Georgia Retina in
Research Title: Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD) Sponsor: Allergan Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: The objective of this study is to evaluate abicipar for safety and treatment effect in patients with neovascular Age-related Macular Degeneration (AMD). Start Date: June 2018 Recruitment: Enrolling Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC,…
Read More ALLERGAN 206207-012
Posted by: Georgia Retina in
Research Title: Safety and Efficacy of a New Treatment in Combination With Laser for Diabetic Macular Edema Sponsor: Allergan Principal Investigator: Robert Stoltz, M.D., Ph.D Description: This study will evaluate the safety and efficacy of the intravitreal implant of dexamethasone with laser treatment vs. laser treatment alone in patients with diabetic macular edema. Start Date: April 2007 Recruitment: Completed Project Personnel: Leslie…
Read More AREDS2
Posted by: Georgia Retina in
Research Title: Age-Related Eye Disease Study 2 (AREDS2) Sponsor: National Eye Institute (NEI) Principal Investigator: Jay Stallman, M.D. Description: AREDS2 is a multi-center randomized trial of approximately 4,200 participants designed to assess the effects of oral supplementation of high doses of macular xanthophylls (lutein and zeaxanthin) and omega-3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract….
Read More Acucela 4429-202 SEATTLE
Posted by: Georgia Retina in
Research Title: A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration. Sponsor: Acucela Inc Principal Investigator: Mark J. Rivellese, M.D. Description: The purpose of this study is to determine if emixustat hydrochloride (ACU-4429) reduces the rate of…
Read More 
